Literature DB >> 7904640

Anomalous parameter estimates in the one-compartment model with first-order absorption.

R D Purves1.   

Abstract

A difficulty sometimes encountered in least-squares fitting of a one-compartment model with first-order absorption is that estimated values (ka and ke) of the rate constants of absorption and elimination are almost identical, are highly correlated and have very large standard deviations. This anomaly is explained by the existence of a class of data sets for which least-squares estimates of the rate constants are complex quantities. Such data sets may arise either from an unfortunate combination of random (e.g. assay) errors in the concentration values if ka and ke are sufficiently similar in magnitude, or from delayed absorption.

Mesh:

Year:  1993        PMID: 7904640     DOI: 10.1111/j.2042-7158.1993.tb05628.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

1.  Consequence of equal absorption, distribution and/or elimination rate constants.

Authors:  Y Plusquellec; F Courbon; S Nogarede
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.441

2.  Multiple solutions, illegal parameter values, local minima of the sum of squares, and anomalous parameter estimates in least-squares fitting of the two-compartment pharmacokinetic model with absorption.

Authors:  R D Purves
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

3.  The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.

Authors:  E J Begg; R A Robson; D A Saunders; G G Graham; R C Buttimore; A M Neill; G I Town
Journal:  Br J Clin Pharmacol       Date:  2000-01       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.